Response to Comments: MolDX: Blood Product Molecular Antigen Typing

This document is a response-to-comments notice for MolDX LCD DL38333, which renames the policy to 'MolDX: Blood Product Molecular Antigen Typing.' The comment period ran from 10/22/2019 to 12/06/2019; the notice period began 10/22/2020 and the LCD became effective 12/06/2020.

"Response-to-comments notice: LCD DL38333 title revised to 'MolDX: Blood Product Molecular Antigen Typing'; comment period ran 10/22/2019–12/06/2019; notice period began 10/22/2020 and the LCD becom..."

Sign up to see full coverage criteria, indications, and limitations.